Login to Your Account



Earnings Roundup


Friday, February 18, 2011
Acorda Therapeutics Inc., of Hawthorne, N.Y., reported net revenue of $52.3 million from fourth-quarter sales of multiple sclerosis drug Ampyra (dalfampridine). The drug, designed specifically to improve walking ability in MS patients, has been prescribed to about 40,000 people, or 10 percent of the U.S. MS population in the 10 months since its launch.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription